Ceftaroline as salvage therapy for methicillin susceptible Staphylococcus aureus complicated bacteremia

Area of Science:

• Infectious Diseases
• Clinical Pharmacology
• Antimicrobial Stewardship

Background:

• Methicillin-susceptible Staphylococcus aureus (MSSA) infections cause significant morbidity and mortality.
• Cefazolin (CFZ) treatment failures in MSSA infections are increasingly reported, potentially due to the inoculum effect.
• Novel therapeutic strategies are required for severe MSSA infections.

Purpose of the Study:

• To evaluate the clinical characteristics and outcomes of patients with complicated MSSA bacteremia who failed cefazolin therapy.
• To assess the efficacy and safety of ceftaroline fosamil (CPT) as a salvage treatment for these patients.

Main Methods:

• Retrospective chart review of patients with MSSA bacteremia over a 12-month period.
• Identification of patients who experienced treatment failure with cefazolin.
• Analysis of clinical data, treatment regimens (CPT monotherapy or combination), and patient outcomes.

Main Results:

• Five out of 21 patients (24%) with MSSA bacteremia failed cefazolin therapy and were successfully treated with CPT.
• Patients received a median of 10 days of CFZ before switching to CPT.
• Four patients had metastatic spread, and two had endocarditis; all achieved microbiological and clinical cure with CPT.
• One patient discontinued CPT due to neutropenia.

Conclusions:

• Ceftaroline fosamil (CPT) demonstrates potential as an effective salvage therapy for complicated MSSA bacteremia failing cefazolin.
• CPT can be used as monotherapy or in combination with other antibiotics.
• Further investigation is warranted to confirm CPT's role in managing challenging MSSA infections.